AMPA receptor potentiators for the treatment of CNS disorders.
about
The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulationAmpakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expressionTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesStructural and Functional Analysis of Two New Positive Allosteric Modulators of GluA2 Desensitization and DeactivationStudies on an ( S )-2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid (AMPA) Receptor Antagonist IKM-159: Asymmetric Synthesis, Neuroactivity, and Structural CharacterizationAMPA receptor inhibition by synaptically released zincSerotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.Zebrafish: An in vivo model for the study of neurological diseases.Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia.AMPA receptor regulation at the mRNA and protein level in rat primary cortical culturesEffects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals.Lithium acts as a potentiator of AMPAR currents in hippocampal CA1 cells by selectively increasing channel open probability.Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.Glutamatergic modulators: the future of treating mood disorders?Effects of cyclothiazide on GluR1/AMPA receptorsNew targets for rapid antidepressant action.A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Structure and dynamics of AMPA receptor GluA2 in resting, pre-open, and desensitized statesX-ray structures of AMPA receptor-cone snail toxin complexes illuminate activation mechanism.The effects of huperzine A and IDRA 21 on visual recognition memory in young macaquesIdentification of novel modulators for ionotropic glutamate receptor, iGluA2 by in-silico screeningRestoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factorPiracetam improves mitochondrial dysfunction following oxidative stress.New medications for drug addiction hiding in glutamatergic neuroplasticity.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Ionotropic glutamate receptor GluR1 in the visual cortex of hamster: distribution and co-localization with calcium-binding proteins and GABAThe molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptorsGlutamate receptor subunit expression in the rhesus macaque locus coeruleusGlutamate modulators as novel interventions for mood disorders.The free energy landscapes governing conformational changes in a glutamate receptor ligand-binding domainCalcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons.An update on the pharmacology of galantamine.Ionotropic glutamate receptors & CNS disorders.Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disordersAMPA Receptors Are Involved in Store-Operated Calcium Entry and Interact with STIM Proteins in Rat Primary Cortical Neurons.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Are AMPA receptor positive allosteric modulators potential pharmacotherapeutics for addiction?AMPA receptor positive allosteric modulators: a patent review.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionThe glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment
P2860
Q24613593-1B7CBC4B-BC99-4B61-8F0B-54900BC44444Q24652009-BB20EDFF-4DD0-42B9-820D-DF1278580F68Q27023257-2C725E45-6D98-4B4D-8D1E-21D397F21CDBQ27667701-C4050726-3CF0-4F62-80A1-B77A48C24702Q27676563-F048E3AF-DBBC-4E52-8FA7-BF12C6E4B4DAQ30381106-7AF8A8D7-E52E-4FEC-9828-7E85C40F9AD6Q30395943-36952D58-14F4-42B5-AD12-573455B09EA3Q30493208-992A80E6-E347-4E0D-A0C6-1CF306D8877DQ33302991-C00B97DE-011A-414A-AA42-2BBC599899FCQ34038248-93D771CD-27A5-47D4-B4ED-0242D40E49FBQ34118141-871D68AE-E588-4486-9EB8-C9413707571DQ34135203-8EFDBA07-EFC8-4D21-9A1E-F4E443FB0CA3Q34190402-0290D660-1F6D-4527-BF3E-408227A913FDQ34398007-D08E1AB0-2DFF-4C9F-80D5-BF6A5990B502Q34479700-1DC9F732-9C8E-48D5-9048-30EE98A84E8AQ34507177-73AA49CE-D33E-4801-9267-0758390A0319Q34579324-C0FB2981-CEB6-4A72-98CD-A6AF3E98A094Q34679225-C9F9C8C6-F7A9-4C1E-9745-B1B3A5FA1F91Q34679478-2202A396-9A03-4806-B0A1-D91DDA35DC77Q34775101-CA7D7651-4547-4992-9459-38D5143896B7Q34820857-89E96C71-72A7-4C32-BDCB-6DC64AD41689Q35008236-4EE921DA-4CC4-49C6-BBCD-9C5C08E5ACF5Q35098643-A52EFE1A-CAD4-4026-93F9-73CA5DF4E319Q35333393-2292B2C4-DC99-4BB0-B79D-50176F547727Q35661119-504C96D6-5C39-4EBF-815D-4AB0FF52BFB6Q35688252-CC761050-DF9D-43E2-8CC7-C6147900A9CBQ35858251-15F38661-667C-4821-BF85-B655D6CDBE19Q36122888-DDEAAF71-0BD3-4F98-A8B1-50619A3B854BQ36285982-A9CD6083-74E0-45F2-ACE4-138C86B68171Q36528592-B2EE9388-BF10-490F-801F-BFC9625F25E6Q36804911-2D0C3EDB-1CB1-42CB-B713-6102ADC8A6CDQ37016107-05783813-A1F4-47FC-9D0C-069B5ECE63A9Q37143580-F688D295-E670-4B68-9353-06B369DB5E67Q37254517-6D5A5E5D-EC51-48CC-BE40-A7CE2A9F49F2Q37363721-5F0BEC18-63FA-4DE1-97EB-7FF6089BF30BQ37387700-1661D033-6A15-454E-8333-7C874F8D8FDAQ37559271-BCB1BC1A-778C-4846-8596-8350167FFCEEQ38081162-2BFDA2CC-8A85-43E3-B041-EF4981239310Q38125568-2E682815-9B76-4580-9D65-45A7DB2CC843Q38213709-AE8A51E5-CCCE-4757-A166-9F14E49FA644
P2860
AMPA receptor potentiators for the treatment of CNS disorders.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
AMPA receptor potentiators for the treatment of CNS disorders.
@ast
AMPA receptor potentiators for the treatment of CNS disorders.
@en
type
label
AMPA receptor potentiators for the treatment of CNS disorders.
@ast
AMPA receptor potentiators for the treatment of CNS disorders.
@en
prefLabel
AMPA receptor potentiators for the treatment of CNS disorders.
@ast
AMPA receptor potentiators for the treatment of CNS disorders.
@en
P2093
P356
P1476
AMPA receptor potentiators for the treatment of CNS disorders.
@en
P2093
David Bleakman
Dennis M Zimmerman
Eric S Nisenbaum
Michael J O'Neill
P304
P356
10.2174/1568007043337508
P577
2004-06-01T00:00:00Z